Financials
Financial year 2025
Le Conseil International des Excipients Pharmaceutiques - Europe from Brussel, company number BE0501816137, closed financial year 2025 with a result of € 35,090 after tax. For that financial year Le Conseil International des Excipients Pharmaceutiques - Europe recorded a gross margin of € 412,996 and equity of € 1.2 million. Compared with financial year 2024, the result moved from € 95,158 to € 35,090. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 2, 2026.
€ 1.2 million
▲ 3% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 35,090
▼ 63% vs 2024
Profit after tax over the fiscal year.
€ 671,988
▲ 13% vs 2024
Cash and bank balances on the last day of the fiscal year.
People and assets in 2025
€ 378,524
▲ 24% vs 2024
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 9,628
▲ 103% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 60,028
▼ 1% vs 2024
Taxes, VAT and social contributions still to pay.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 356,418 | € 399,928 | € 397,250 | € 412,996 | ▲ 4% |
| Profit after taxes | € -10,308 | € 64,024 | € 95,158 | € 35,090 | ▼ 63% |
| Equity | € 987,931 | € 1,051,955 | € 1,147,112 | € 1,182,202 | ▲ 3% |
| Total debts | € 76,917 | € 84,830 | € 88,250 | € 93,656 | ▲ 6% |
| Cash | € 799,760 | € 686,346 | € 596,550 | € 671,988 | ▲ 13% |
| Retained profit | € 806,702 | € 870,726 | € 965,884 | € 1,000,974 | ▲ 4% |
| Balance sheet total | € 1,074,848 | € 1,146,784 | € 1,245,363 | € 1,285,858 | ▲ 3% |
By gross margin, Le Conseil International des Excipients Pharmaceutiques - Europe ranks 96th of 130 companies with main activity “Activiteiten van bedrijfs- en werkgeversorganisaties” in Brussel that publish figures (fiscal year 2025).
Key figures of Le Conseil International des Excipients Pharmaceutiques - Europe, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
Ask about Le Conseil International des Excipients Pharmaceutiques - Europe the way you would ask their accountant.
Answers from the filed annual accounts, the Belgian Official Gazette and the CBE register.
Connect ChatGPT or Claude for free- ChatGPT
- Claude
Free account, no payment card. Key figures unlimited, the annual accounts and deeds of 10 companies a month. Need more? Get in touch, we are looking for our first pilot users.
What happened to Le Conseil International des Excipients Pharmaceutiques - Europe?
What happened at Le Conseil International des Excipients Pharmaceutiques - Europe in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 35,090 (▼ 63% vs 2024). Source: NBB ↗
- New establishment in Brussel. KBO
- Start of the company according to the CBE. KBO
In short
From € 10,308 loss in 2022 to € 35,090 profit in 2025.
Paid € 4,425 in corporate taxes since 2022.
Best year ever: 2024, with € 95,158 profit.
Management
Behind Le Conseil International des Excipients Pharmaceutiques - Europe are Mahmud Yunis, Karsten Diehl, Jesus Javier Rivas Garrido, Karine Aranzana Roth, Lotte Kok and Frank Milek.
Directors
According to the 2025 annual accounts
Mahmud Yunis
Director
Karsten Diehl
Administrateur / Trésorier
Jesus Javier Rivas Garrido
Director
Karine Aranzana Roth
Chairman of the board
Lotte Kok
Director
Frank Milek
Director
Kevin Hughes
Vice-chairman of the board
Establishments
Establishment units
Physical locations of this company
Maria van Bourgondiëstraat 52 box 2
1000 Brussel
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 7 companies are registered at this address.
All companies at this address →EUROCITY
€ 1.8 million gross margin · 2025
Stichting Wereld Dorpen voor Kinderen
€ 453,380 gross margin · 2025
FEDERATION EUROPEENNE DE L'INDUSTRIE DU SPORT
€ 620,228 gross margin · 2024
Eurocity Holdings
€ 1.4 million gross margin · 2025
EXCiPACT
€ 198,026 gross margin · 2025
+2 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Similar companies in Brussel
Same main activity (Activiteiten van bedrijfs- en werkgeversorganisaties), 265 active companies in Brussel, largest first.
VLAAMSE VERENIGING VOOR ICT-PERSONEEL
€ 50.6 million revenue · 2024
Vlaams Centrum voor Agro- en Visserijmarketing
€ 17 million revenue · 2025
Association Pharmaceutique Belge-Algemene Pharmaceutische Bond
€ 12.4 million revenue · 2023
€ 10.4 million revenue · 2025
€ 9.5 million revenue · 2025
€ 8 million revenue · 2025
Website
Technologies
Hosting & Email
Email provider
Microsoft 365
Hosting
COMBELL-AS, BE
DNS
OVH DNS
Domain
Domain
ipec-europe.org
Registered
2006-08-26
Registrar
OVH sas
Expires
2026-08-26
Website info
Features
Security
Details
- Company number
- 0501.816.137
- VAT number
- BE 0501.816.137
- Registered office
- Maria van Bourgondiëstraat 52 bus 2, 1000 Brussel
- Names & denominations
- Le Conseil International des Excipients Pharmaceutiques - Europe · IPEC Europe
- Enterprise type
- Rechtspersoon
- Legal form
- Non-profit association
- Legal situation
- Normale toestand
- Start date
- 7 December 2012
- Peppol
- Active · Active since 21 Oct 2025
- Contact
- ipec-europe.org
- Activities · NACE
Activiteiten van bedrijfs- en werkgeversorganisaties
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering